Scienture Holdings, Inc. has entered into a securities purchase agreement with institutional investors.
The agreement is for the purchase of 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds from the offering are expected to be approximately $3.9 million.
Offering Details
3,225,000 shares of common stock to be purchased at $1.20 per share.
Expected Gross Proceeds
Approximately $3.9 million gross proceeds before deducting fees.
Closing Date
The offering is set to close on August 15, 2025.
- Scienture Holdings, Inc. is focusing on providing enhanced value to patients, physicians, and caregivers through novel specialty products.
- Maxim Group LLC is acting as the sole placement agent for the offering.
This registered direct offering showcases Scienture Holdings, Inc.'s commitment to enhancing value in the pharmaceutical industry and expanding its operations.